Blake builds and invests in companies that move atoms and bits. His recent investments include Neuralink, Vial, Benchling and Freenome. Blake was most recently a General Partner at GV for a decade where he led investments in tech and healthcare companies. Some of his biotech investments include Forty Seven (Nasdaq: FTSV), Arcus (Nasdaq: RCUS), Denali (Nasdaq: DNLI), and Grail (acquired by Illumina). Blake’s incubations include Pact Pharma, a neoantigen T cell therapy company.
Blake received a PhD and MS in bioengineering from Stanford University and holds a BS in biomedical engineering and BS in economics from Duke University.
Brian Armstrong is the co-founder and CEO of Coinbase, having grown it from inception to public company with thousands of employees and billions of dollars in revenue.
He is deeply passionate about accelerating science and improving human healthspan. He brings experience in software, machine learning, organization design, fundraising, leadership, and team building.
He holds a master’s degree in computer science and a bachelor’s degree in economics from Rice University.
Greg accelerates research by using statistical methods to predict the outcomes of biological experiments.
Prior to NewLimit, Greg led and contributed to special projects at Amazon. Before that, he led the development of novel machine learning methods at the Allen Institute for Cell Science. Greg is best known for inventing technology to label diverse tissue structures in silico and developing generative models to propose and prioritize hypotheses for high-throughput experimentation.
Greg received a PhD in computational biology and a MS in biomedical engineering from Carnegie Mellon University, and BS in bioengineering from California Lutheran University.
Jacob uses genomics and machine learning methods to identify and manipulate the genetic programs that define cell identity.
Prior to NewLimit, Jacob led a research laboratory focused on epigenetic reprogramming as a Principal Investigator and Computational Fellow at Calico. His program developed methods to infer and perturb cell identity programs and leveraged these tools to discover reprogramming strategies that restore youthful features in aged cells.
Jacob received a Ph.D. in stem cell biology from the University of California San Francisco.
Alex Marson is a professor at UCSF, scientific director of human health at the Innovative Genomics Institute (IGI), and head of the Gladstone-UCSF Institute of Genomic Immunology. Dr. Marson’s research goal is to understand the genetic circuits that control human immune cell function, and his team has pioneered new CRISPR gene editing technologies that offer more precise ways to rewrite DNA programs in human immune cells.
Dr. Marson received an AB and an MD from Harvard, a PhD from MIT, and completed his internal medicine residency at Brigham and Women’s Hospital, and an infectious diseases fellowship at UCSF.
Dr. E. John Wherry is the Barbara Schiffrin President’s Distinguished Professor at the Perelman School of Medicine at the University of Pennsylvania. John also serves as the Chair of the Department of Systems Pharmacology and Translational Therapeutics and the Director of the Institute for Immunology at the Perelman School of Medicine.
John’s work has pioneered the field of T cell exhaustion and revealed the molecular mechanisms of diverse T cell identity programs. Among other contributions, his group has defined the transcriptional program of T cell exhaustion, revealed the functional characteristics of exhausted T cells, and discovered the role of inhibitory receptors such as PD-1 in the exhaustion program. The Wherry lab has demonstrated that exhaustion programs play an important role in limiting the effectiveness of adaptive immune responses to both chronic infection and cancer and explored checkpoint blockade mechanisms to re-invigorate exhausted cells. To enable these discoveries, the Wherry lab has employed emerging epigenetic profiling technologies to define T cell identity programs, identify the molecular drivers of these transcriptional programs, and delineate distinct T cell fates.
Dr. Wherry holds a Ph.D. in Immunology from the Thomas Jefferson University and a B.S. from the Pennsylvania State University.
Mark M. Davis is the Director of the Stanford Institute for Immunology, Transplantation and Infection, a professor of microbiology and immunology, and a Howard Hughes Medical Institute Investigator.
Dr. Davis is well known for identifying many of the T-cell receptor genes, which are responsible for the ability of these cells to recognize a diverse repertoire of antigens. His current research focuses on obtaining a “systems level” understanding of the human immune system, including the steady state and vaccine responses of old and young subjects.
Dr. Davis received a BA from Johns Hopkins University, and a PhD from the California Institute of Technology.
Alex oversees NewLimit's talent and people function by working to ensure that top talent enters and stays at the company.
Prior to NewLimit Alex was the Head of Talent at Dave where he built the recruiting function from the ground up. During his time at Uber he led talent teams across the companies new business lines.
Alex is a former CPA and received his BA in Business Economics and Accounting from UC Santa Barbara.
Alex develops and applies functional genomics technologies that enable high-throughput, single cell screens of gene function.
Before joining NewLimit, Alex led CRISPR-RNA research as a postdoctoral scientist at the New York Genome Center in Neville Sanjana’s lab. At NYGC, he developed new CRISPR tools for high-throughput genetic screens with multimodal single cell read outs to dissect the inner workings of the human transcriptome.
Alex received a PhD and MS in Biomedical Sciences from the San Luis Potosi University, Mexico.
Ben contributes to T cell reprogramming discovery platforms and develops read-outs to measure rejuvenated function of reprogrammed cells.
Prior to joining NewLimit, Ben built cell manufacturing pipelines that enabled CRISPRa-driven, genome-scale gain-of-function screens in primary CAR-T cells.
Ben received a Ph.D. in Molecular Medicine and Mechanisms of Disease from the University of Washington.
Burak develops and uses single cell technologies and functional genomic techniques that enable large scale screens of epigenetic reprogramming at NewLimit.
Prior to NewLimit, Burak led a cross-functional team at Inscripta and contributed to the development of the first bench-top genome engineering instrument as well as single cell genomic assays for characterizing gene editing outcomes.
Burak received a PhD degree from MIT, a MS degree from Stanford, and a BS degree from METU, all in electrical engineering.
Conner is a Data Scientist on the Predict team at NewLimit working on Building pipelines & computational infrastructure for single-cell genomics data and developing models to predict cell function.
Prior to NewLimit, Conner completed his PhD in Computational and Systems Biology at MIT, working in the Shalek Lab. Outside of work, Conner enjoys rock climbing, cooking, and taking ice baths.
Dave contributes to the design and execution of single cell functional genomics screens at NewLimit to identify epigenetic reprogramming factors.
Prior to joining NewLimit, Dave worked as a postdoctoral fellow in Paul Khavari's lab at Stanford University using single cell functional genomics screening approaches to identify epigenetic regulators of epithelial homeostasis.
Dave received a Ph.D. in molecular biology from the University of Georgia and a B.S. in biology from the University of Virginia.
.webp)
Jenna performs operational and administrative functions for NewLimit, including event management, HR, vendor management, talent acquisition, and leadership support.
Prior to NewLimit, Jenna worked as an Administrative Business Partner at Google Ventures, where she specialized in supporting women's health investments. She has also served in various operational capacities for international non-profit healthcare initiatives.
Jenna received a B.S. in Public Health from Brigham Young University with an emphasis in international development and epidemiology.
John uses in vitro models to understand how T cells are impaired in aging and to quantify the impacts of epigenetic reprogramming on cell state and function.
Prior to joining NewLimit, John was an Associate Director at 3T Biosciences. There, he led in vitro immunology efforts supporting the discovery and early preclinical development of cell therapy and bispecific T cell engager drug candidates for the treatment of solid tumors.
John completed a postdoctoral fellowship in molecular and cellular immunology at the University of Chicago. He received a PhD in Biochemistry from UCSF and a BS in Biochemistry from the University of Wisconsin.
Lucas builds machine learning models to predict the outcome of targeted perturbations in single-cell experiments.
Prior to NewLimit, Lucas participated in research projects to develop novel computational methods for analyzing single-cell data. Lucas developed interpretable deep generative models integrating prior biological information about gene programs to shed light on cellular identity and how it is affected by perturbations.
Lucas received a PhD in computational biology from the University of California Santa Cruz, and a MS and Biotech engineering degree from the Strasbourg Graduate School of Biotechnology in France.
Nader contributes to the design and execution of pooled perturbation screens to identify epigenetic reprogramming factors.
Before joining NewLimit, Nader worked as a scientist at Mammoth Biosciences, helping build pooled screening platforms for predicting the activity of novel nucleases. During his graduate work, Nader developed a high-throughput screen to systematically profile human transcriptional regulators and invented potent CRISPR-based epigenetic engineering tools.
Nader received a Ph.D. in molecular genetics from the University of Toronto.
Wes develops in vitro models of epigenetic aging and executes high throughput screens to identify factors that rejuvenate cellular function.
Prior to joining NewLimit, Wes was a stem cell biologist at Maze Therapeutics. During his academic career, Wes’ experience has spanned hiPSC disease modeling, functional genomics, small molecule optimization and synthetic biology.
Wes received a PhD in Biomedical Science from Sanford Burnham Prebys Medical Discovery Institute and a BA in Biochemistry from the University of San Diego.
Yana facilitates discovery of aging interventions by optimizing high-throughput single cell screens.
Prior to NewLimit, Yana was a postdoctoral researcher at the University of California San Francisco, working to elucidate mechanisms of aging from the perspective of epigenetic regulation of ribosomal DNA.
Yana received a PhD in genetics from the University of California Davis.
